Skip to main content
LTRN
NASDAQ Life Sciences

Director Buys $100K in Recent Offering, Signaling Confidence

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.1
Mkt Cap
$35.384M
52W Low
$1.11
52W High
$5.744
52W Position info
179% above low
Off High info
46% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

LTRN has more than doubled off its 52-week low of $1.11 on elevated volume (2.0× avg).

Summary

Director Lee Troy Schalop purchased $100,001 of common stock and warrants in Lantern Pharma's recent offering, indicating insider confidence following the capital raise.


Key Events · Ownership and Investor Activity · LTRN

  • Director Participates in Offering

    Director Lee Troy Schalop acquired $100,001 worth of common stock in the company's offering that closed on May 14, 2026.

  • Acquisition Details

    The purchase involved 48,544 shares of common stock at a price of $2.06 per share on May 12, 2026.

  • Warrant Component Included

    The acquisition also included 48,544 common stock purchase warrants with an exercise price of $2.27, exercisable starting November 14, 2026.

  • Context of Recent Offering

    This insider purchase directly follows the company's announcement and finalization of a $4.4 million offering of common stock and pre-funded warrants, as reported in a 424B5 filing today.


Analysis · LTRN · Life Sciences

A director's participation in a recent offering, acquiring $100,001 worth of common stock, is a positive signal. This insider purchase demonstrates conviction in the company's prospects, especially as it follows the finalization of a $4.4 million offering. While offerings can be dilutive, a director investing their own capital suggests a belief that the company's valuation will improve.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LTRN was trading at $3.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.4M. The 52-week trading range was $1.11 to $5.74. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LTRN - Latest Insights

LTRN
Oct 08, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.830
Real-time Price: $0.3915 info
Change: -$0.4385 (-53%) info
Market Cap: $5.81M info
LTRN
Oct 07, 2026, 8:31 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.3915 info
Change: -$0.5585 (-59%) info
Market Cap: $5.81M info
LTRN
Oct 01, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.00
Real-time Price: $0.3915 info
Change: -$0.6085 (-61%) info
Market Cap: $5.81M info
LTRN
Sep 30, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.01
Real-time Price: $0.3915 info
Change: -$0.6185 (-61%) info
Market Cap: $5.81M info
LTRN
Sep 30, 2026, 9:29 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.09
Real-time Price: $0.3915 info
Change: -$0.6935 (-64%) info
Market Cap: $5.81M info